Directorate Change

GlaxoSmithKline PLC
07 December 2007


Issued -  Friday 7 December 2007, London, UK - LSE Announcement

GlaxoSmithKline Announces Appointments To The Board Of Directors

GlaxoSmithKline plc (GSK) today announced the following executive appointments
and changes:

  • Andrew Witty, CEO Designate, and Chris Viehbacher, President US
    Pharmaceuticals, have been appointed Executive Directors and will join the
    Board of the Company with effect from 31st January 2008.

  • Eddie Gray, currently Senior Vice President and General Manager
    Pharmaceuticals UK, will succeed Andrew Witty as President, Pharmaceuticals
    Europe for GlaxoSmithKline. Eddie will assume his new position on 1st
    January 2008.

  • David Stout, currently President of Pharmaceuticals, will leave the
    company in February 2008.

Commenting on the changes, Sir Christopher Gent, Chairman, said: "I am very
pleased that both Andrew and Chris will be joining the Board. In doing so, we
have increased the overall number of executive directors on the Board, and
ensured that it remains strongly aligned to GSK's strategy and operational
performance."

JP Garnier, Chief Executive Officer, said: "I would like to thank David
sincerely for his significant contribution to GSK and for the support he has
given me over many years. We wish him well in his future endeavours. Andrew and
I would also like to congratulate Eddie on his appointment and welcome him to
the Corporate Executive Team. We wish him every success in managing our European
pharmaceuticals business."

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and
healthcare companies - is committed to improving the quality of human life by
enabling people to do more, feel better and live longer.


Notes to Editors

Eddie Gray: Biography

Eddie Gray was appointed Senior Vice President and General Manager,
Pharmaceuticals UK for GlaxoSmithKline in 2001. He is a member of the
Pharmaceuticals Europe Executive Team. Previously, he was Vice President &
General Manager, SmithKline Beecham Pharmaceuticals, Canada, and a member of
SmithKline Beecham's Executive Management Team for North America.

Eddie joined SmithKline Beecham in 1988 as National Sales Manager. He held
various positions in the UK company of increasing responsibility, including Head
of Hospital Sales, Marketing Manager for Anti-Infective products and Business
Unit Director for the UK Pharmaceuticals General Medicine business before moving
to the US, where he assumed responsibility for Market Research for the US
Pharmaceuticals business.  He later became Vice President & Director of
Anti-Infectives Marketing, then Vaccines Marketing in the US, before assuming
his role in Canada.

Eddie serves on the Board of Management of the Association of the British
Pharmaceutical Industry (ABPI) and chairs the ABPI Economic Strategy Group.  He
is an advisory board member of Opportunity Now, an organisation for employers
who are committed to creating an inclusive workplace for women; and a Trustee of
Project HOPE UK which aims to make health care available for people around the
globe, especially children.

Eddie holds an honours degree in Chemistry and Management Studies from the
University of London, and an MBA from the Cranfield School of Management in the
UK. He is married with three daughters.



Enquiries:

UK Media enquiries:                      Philip Thomson          [phone]
                                         Claire Brough           [phone]
                                         Alice Hunt              [phone]
                                         Joss Mathieson          [phone]

US Media enquiries:                      Nancy Pekarek           [phone]
                                         Mary Anne Rhyne         [phone]

European Analyst/Investor enquiries:     David Mawdsley          [phone]
                                         Sally Ferguson          [phone]

US Analyst/ Investor enquiries:          Frank Murdolo           [phone]
                                         Tom Curry               [phone]


                      This information is provided by RNS
            The company news service from the London Stock Exchange